Lymphovascular space invasion does not predict vaginal relapses in stage I endometrioid adenocarcinoma of the endometrium

Annals of Diagnostic Pathology

Volumn 12, Issue 2, 2008, Pages 112-117

  Desrosiers, Laurephile ^a   Fadare, Oluwole ^b,c   Xiao, Zhefu F ^a   Dresser, Karen ^a   Wang, Sa A ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b WILFORD HALL MEDICAL CENTER   (United States)

^c Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Capillary space invasion; Endometrial endometrioid adenocarcinoma; Lymphovascular space invasion; Relapse; Uterus; Vaginal recurrence

Indexed keywords

CD34 ANTIBODY; CYTOKERATIN; VON WILLEBRAND FACTOR;

ADULT; AGE DISTRIBUTION; AGED; ANALYSIS OF VARIANCE; ARTICLE; BODY MASS; CANCER INVASION; CANCER RECURRENCE; CANCER RELAPSE; CANCER TISSUE; DIABETES MELLITUS; ENDOMETRIUM CARCINOMA; FEMALE; FISHER EXACT TEST; FOLLOW UP; HUMAN; HUMAN TISSUE; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MYOMETRIUM; PARAAORTIC LYMPH NODE; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; UNIVARIATE ANALYSIS; VAGINA CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, ENDOMETRIOID; COMBINED MODALITY THERAPY; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS, SECOND PRIMARY; PREDICTIVE VALUE OF TESTS; VAGINAL NEOPLASMS;

EID: 39749129088     PISSN: 10929134     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.anndiagpath.2007.05.009     Document Type: Article

References (37)

1. Jemal A., Tiwari R.C., Murray T., Ghafoor A., Samuels A., Ward E., et al. Cancer statistics, 2004. CA Cancer J Clin 54 (2004) 8-29
2. Creasman W.T., Odicino F., Maisonneuve P., Beller U., Benedet J.L., Heintz A.P., et al. Carcinoma of the corpus uteri. Int J Gynaecol Obstet 83 Suppl 1 (2003) 79-118
3. Clement P.B., and Young R.H. Endometrioid carcinoma of the uterine corpus: a review of its pathology with emphasis on recent advances and problematic aspects. Adv Anat Pathol 9 (2002) 145-184
4. Prat J. Prognostic factors of endometrial carcinoma. Hum Pathol 35 (2004) 649-662
5. Viani G.A., Patia B.F., Pellizzon A.C., De Meio M.D., Novaes P.E., et al. High-risk surgical stage 1 endometrial cancer: analysis of treatment outcome. Radiat Oncol 1 1 (2006) 24 [Electronic publication ahead of print]
6. Ambros R.A., and Kurman R.J. Identification of patients with stage I uterine endometrioid adenocarcinoma at high risk of recurrence by DNA ploidy, myometrial invasion, and vascular invasion. Gynecol Oncol 45 (1992) 235-239
7. Ambros R.A., and Kurman R.J. Combined assessment of vascular and myometrial invasion as a model to predict prognosis in stage I endometrioid adenocarcinoma of the uterine corpus. Cancer 69 (1992) 1424-1431
8. Hanson M.B., van Nagell Jr. J.R., Powell D.E., et al. The prognostic significance of lymph-vascular space invasion in stage I endometrial cancer. Cancer 55 (1985) 1753-1757
9. Inoue Y., Obata K., Abe K., et al. The prognostic significance of vascular invasion by endometrial carcinoma. Cancer 78 (1996) 1447-1451
10. Sivridis E., Buckley C., and Fox H. The prognostic significance of lymphatic vascular space invasion in endometrial adenocarcinoma. Br J Obstet Gynaecol 94 (1987) 991-994
11. Tsuruchi N., Kaku T., Kamura T., et al. The prognostic significance of lymphovascular space invasion in endometrial cancer when conventional hematoxylin and eosin staining is compared to immunohistochemical staining. Gynecol Oncol 57 (1995) 307-312
12. Bell J., Minnick A., Reid G., et al. Relationship of nonstaging pathologic risk factors to lymph node metastasis and recurrence in clinical stage 1 endometrial carcinoma. Gynecol Oncol 66 (1997) 388-392
13. Gal D., Recio F., Zamurovic D., et al. Lymphvascular space involvement: a prognostic indicator in endometrial adenocarcinoma. Gynecol Oncol 42 (1991) 142-145
14. Tornos C., Silva E., El-Naggar A., and Burke T.W. Aggressive stage I grade I endometrial carcinoma. Cancer 70 (1992) 790-798
15. Cohn D.E., Horowitz N.S., Mutch D.G., et al. Should the presence of lymphvascular space involvement be used to assign patients to adjuvant therapy following hysterectomy for unstaged endometrial cancer?. Gynecol Oncol 87 (2002) 243-246
16. Zaino R.J., Kurman R.J., et al. Pathological models to predict outcome for women with endometrial adenocarcinoma: the importance of the distinction between surgical stage and clinical stage. Cancer 77 (1996) 1115-1121
17. Mariani A., Webb M.J., Keeney G.L., Lesnick T.G., and Podratz K.C. Surgical stage I endometrial cancer: predictors of distant failure and death. Gynecol Oncol 87 (2002) 274-280
18. Kadar N., Malfetano J.H., and Homesley H.D. Determinants of survival of surgically staged patients with endometrial carcinoma histologically confined to the uterus: implications for therapy. Obstet Gynecol 80 (1992) 655-659
19. Aalders J.G., vd Syde R., Poppema S., Szabo B.G., and Janssens J. Prognostic factors and changing trends in the treatment of stage I endometrial cancer: a clinical and histopathological study of 182 patients. Int J Radiat Oncol Biol Phys 10 (1984) 2083-2088
20. Ayhan A., Tuncer Z.S., Tuncer R., et al. Risk factors for recurrence in clinically early endometrial carcinoma: an analysis of 183 consecutive cases. Eur J Obstet Gynecol Reprod Biol 57 (1994) 167-170
21. MacLeod C., Fowler A., Duval P., D'Costa I., Dalrymple C., Firth I., et al. High-dose-rate brachytherapy alone post-hysterectomy for endometrial cancer. Int J Radiat Oncol Biol Phys 42 (1998) 1033-1039
22. Morrow C.P., Bundy B., Kurman R., et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a gynecologic oncology group study. Gynecol Oncol 40 (1991) 55-65
23. Keys H.M., Roberts J.A., Brunetto V.L., Zaino R.J., Spirtos N.M., Bloss J.D., et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 92 (2004) 744-751
24. Petereit D.G., Tannehill S.P., Grosen E.A., Hartenbach E.M., and Schink J.C. Outpatient vaginal cuff brachytherapy for endometrial cancer. Int J Gynecol Cancer 9 (1999) 456-462
25. Mariani A., Webb M., Keeney G., et al. Predictors of lymphatic failure in endometrial cancer. Gynecol Oncol 84 (2002) 437-442
26. Lee K.R., Vacek P.M., and Belinson J.L. Traditional and nontraditional histopathologic predictors of recurrence in uterine endometrioid adenocarcinoma. Gynecol Oncol 54 (1994) 10-18
27. Horowitz N.S., Peters III W.A., Smith M.R., Drescher C.W., Atwood M., and Mate T.P. Adjuvant high dose rate vaginal brachytherapy as treatment of stage I and II endometrial carcinoma. Obstet Gynecol 99 (2002) 235-240
28. Mariani A., Dowdy S.C., Keeney G.L., Haddock M.G., Lesnick T.G., and Podratz K.C. Predictors of vaginal relapse in stage I endometrial cancer. Gynecol Oncol 97 (2005) 820-827
29. Alektiar K.M., McKee A., Venkatraman E., McKee B., Zelefsky M.J., Mychalczak B.R., et al. Intravaginal high-dose-rate brachytherapy for Stage IB (FIGO Grade 1, 2) endometrial cancer. Int J Radiat Oncol Biol Phys 53 (2002) 707-713
30. Irwin C., Levin W., Fyles A., Pintilie M., Manchul L., and Kirkbride P. The role of adjuvant radiotherapy in carcinoma of the endometrium-results in 550 patients with pathologic stage I disease. Gynecol Oncol 70 (1998) 247-254
31. Scholten A.N., van Putten W.L., Beerman H., Smit V.T., Koper P.C., Lybeert M.L., et al. Postoperative radiotherapy for Stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review. Int J Radiat Oncol Biol Phys 63 (2005) 834-838
32. Creutzberg C.L., van Putten W.L., Koper P.C., Lybeert M.L., Jobsen J.J., Warlam-Rodenhuis C.C., et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 355 (2000) 1404-1411
33. Creutzberg C.L., van Putten W.L., Koper P.C., Lybeert M.L., Jobsen J.J., Warlam-Rodenhuis C.C., et al. Survival after relapse in patients with endometrial cancer: results from a randomized trial. Gynecol Oncol 89 (2003) 201-209
34. Ackerman I., Malone S., Thomas G., Franssen E., Balogh J., and Dembo A. Endometrial carcinoma-relative effectiveness of adjuvant irradiation vs therapy reserved for relapse. Gynecol Oncol 60 (1996) 177-183
35. Koh W.J., Tran A.B., Douglas J.G., and Stelzer K.J. Radiation therapy inendometrial cancer. Best Pract Res Clin Obstet Gynaecol 15 (2001) 417-432
36. Alektiar K.M. When and how should adjuvant radiation be used in early endometrial cancer?. Semin Radiat Oncol 16 3 (2006) 158-163
37. Creutzberg C.L., van Putten W.L., Warlam-Rodenhuis C.C., van den Bergh A.C., de Winter K.A., Koper P.C., et al. Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial. J Clin Oncol 22 (2004) 1234-1241